This real-world study evaluated the changes in HbA1c and CGM metrics associated with use of the implantable 180-day Eversense CGM System (Eversense) in patients with type 1 diabetes.
Clinical Use of a 180-Day Implantable Glucose Sensor Improves Glycated Hemoglobin and Time in Range in Patients with Type 1 Diabetes
Di Molfetta, Sergio;Cignarelli, Angelo;Laviola, Luigi;
2020-01-01
Abstract
This real-world study evaluated the changes in HbA1c and CGM metrics associated with use of the implantable 180-day Eversense CGM System (Eversense) in patients with type 1 diabetes.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
